MANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITIS
https://doi.org/10.15690/vsp.v12i3.687
Abstract
A history case of a patient with psoriatic arthritis, characterized by severe disease course, systemic symptoms, significantly increased laboratory markers, polyarticular syndrome, typical skin and nails changes, rapid development of patient’s disability and low quality of his and his family life is presented in this article. The authors showed high efficacy of treatment with biological agent — etanercept. In 3 months of treatment non-active stage of disease was achieved, in 9 months — clinical and laboratory remission, not only of the articular syndrome, but also of the extra-articular and dermatological manifestations and laboratory markers of the activity.
About the Authors
E. I. Alexeeva
Scientific Centre of Children Health of RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University,
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
A. N. Fetisova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
S. I. Valieva
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children Health of RAMS, Moscow
Russian Federation
Russian Federation
E.G. Chistyakova
Scientific Centre of Children Health of RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Landells I., MacCallum C., Khraishi M. The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett. 2008; 13 (4): 4–7.
2. Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.
3. Bzarova T.M., Alekseeva E. I., Peterkova V. A. Voprosi sovremennoi pediatrii — Current Pediatrics. 2006; 5 (5): 13–18.
4. Alekseeva E. I., Bzarova T. M., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2012; 11 (4): 82–88.
5. Alekseeva E. I., Lisitsin A. O., Karagulyan N. A. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (03): 88–94.
6. Lisitsin A. O., Alekseeva E. I., Bzarova T. M. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 115–120.
7. Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 2007; 8 (3): 143–155.
8. Mrowietz U., Barth J., Boehncke W. H., Rosenbach T., Wozel G. Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept. J. Dtsch. Dermatol. Ges. 2005; 3 (6): 470–472.
9. Bonafede M., Johnson B. H., Fox K. M., Watson C., Gandra S. R. Treatment patterns with etanercept or adalimumab for psoriatic diseases in a real-world setting. J. Dermatol. Treat. 2013. PMID: 23441722 [PubMed — as supplied by publisher].
10. Alekseeva E. I., Valieva S. I., Denisova R.V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–56.
11. Yubo C., Xiaosheng L. Clinical trial of etanercept tapering in idiopathic arthritis during remission. Rheumatol. Int. doi: 10.1007/s00296-012-2642-7. 2013/
12. Denisova R. V., Alekseeva E. I., Al'bitskii V.Yu. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (03): 18–26.
13. Gallyamova Yu. A. Lechashhij vrach — Practicing Doctor. 2008; 03.
14. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 2011; 63 (4): 465–482.
15. Baranov A. A., Alekseeva E. I., Bzarova T. M. Voprosi sovremennoi pediatrii — Current Pediatrics. 2013; 12 (1): 37–31.
16. Petty R. E., Southwood T. R., Manners P., Baum J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton. 2001. J. Rheumatol. 2004; 31 (2): 390–392.
17. Hawrot A. C., Metry D. W., Theos A. J., Levy M. L. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr. Dermatol. 2006; 23 (1): 67–71.
18. Alekseeva E. I., Alekseeva A. M., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (4): 30–44.
19. Kozlova A. L., Alekseeva E. I., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (02): 20–26.
20. Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 2007; 8 (3): 143–155.
21. de Vries H. S., van Oijen M. G., Driessen R. J., de Jong E. M., Creemers M. C., Kievit W., de Jong D. J. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Brit. J. Clin. Pharmacol. 2011; 71 (1): 7–19. Doi: 10.1111/j.1365- 2125.2010.03760.x.
22. De Sanctis S., Marcovecchio M. L., Gaspari St. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J. Rheumatol. 2013; 40: 6.
23. Trachana M., Pratsidou-Gerts P., Badouraki M. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2–10-year etanercept exposure. Clin. Rheumatol. Doi: 10.1007/S10067-013-2261-Z. 2013.
24. Bracaglia C., Buonuomo P. S., Tozzi Al. E. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J. Rheumatol. 2012; 39: 6.
Review
For citations:
Alexeeva E.I., Bzarova T.M., Fetisova A.N., Valieva S.I., Sleptsova T.V., Isaeva K.B., Denisova R.V., Mitenko E.V., Chistyakova E. MANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITIS. Current Pediatrics. 2013;12(3):90-96. (In Russ.) https://doi.org/10.15690/vsp.v12i3.687
Views:
706
Email this article 
